Systemic glucocorticoid treatment in rheumatoid arthritis - A debate

Scandinavian Journal of Rheumatology

Volumn 27, Issue 4, 1998, Pages 247-251

  Kirwan, John R ^a   Russell, Anthony S ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Clinical practice; Debate; Steroids

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTISONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ARTHRITIS; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STEROID THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRA-ARTICULAR; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0031717329     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097498442343     Document Type: Review

References (25)

1. Byron MA, Mowat AG. Corticoglucocorticoids prescribing in rheumatoid arthritis the fiction and the fact. Br J Rheumatol 1985;24:164-6.
2. Hench PS, Kendall EC, Slocumb CH, et al. Effects of a hormone of the adrenal cortex (17-hydroxy-11 dehydrocroticosterone: compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Preliminary report. Proceedings of Staff Meetings of Mayo Clinic 1949;24:181-97.
3. Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. Br Med J 1954;29:1223-7.
4. Empire Rheumatism Council. Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic in the long term treatment of rheumatoid arthritis. Ann Rheum Dis 1955;14:353-67.
5. Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1960;19:331-37.
6. Berry H, Huskisson EC. Isotopic indices as a measure of inflammation in rheumatoid arthritis. Ann Rheum Dis 1974;33:523-5.
7. Boardman PL, Dudley Hart F. Clinical measurement of the anti-inflammatory effects of salicilates in rheumatoid arthritis. Br Med J 1967;4:264-8.
8. Jasani MK, Downie WW, Samuels BM, Buchanan WW. Ibuprofen in rheumatoid arthritis. Scand J Rheumatol 1973;2:71-7.
9. Kirwan JR and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
10. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
11. West HF. Rheumatoid arthritis: the relevance of clinical knowledge to research activities. Abs World Med 1967;41:401-17.
12. Byron MA, Kirwan JR. Corticoglucocorticoids in rheumatoid arthritis: Is a trial of their 'disease modifying' potential feasible? Ann Rheum Dis 1986;46:171-3.
13. Hickling P, Jacoby RK, Kirwan JR. Joint destruction recommences after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1996;35 Suppl 2:22.
14. Pincus T, Brooks RH, Callaghan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Annals Int Med 1994;120:26-34.
15. Scott DL, Coulton BL, Chapman JH, Bacon PA, Popert AJ. The long term effect of treating rheumatoid arthritis. J R Coll Phys Lond 1983;17:79-85.
16. Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis over 20 years. Clinical symptoms, radiological signs, treatment, mortality and prognostic significance of early features. Clinical Rheumatology 1987;6 Suppl 2:5-11.
17. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
18. Woolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
19. Leigh JP, Fries JF. Mortality prediction among 263 patients with rheumatoid arthritis. J Rheumatol 1991;18:1307-19.
20. Criswell LA, Henke CJ. What explains the variation among rheumatologists in the use of prednisolone and second line agents for the treatment of rheumatoid arthritis. J Rheumatol 1995;22:829-35.
21. Laan RFJM, van Riel PLCM, van de Putte LBA, van Eming LJTO, van't Hof MA, Lemmens JAM. Low dose prednisolone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Int Med 1993;119:963-8.
22. Reid DM, Cooper C, Kirwan JR. Effects of corticosteroids on bone mass over 2 years when used in the management of early rheumatoid arthritis. Br J Rheumatol 1996;35 Suppl 1:210.
23. Cooper AM, O'Sullivan MM, Clements D, Compston JE. Long term follow up of spinal trabecular bone mineral density in women with non-steroid treated rheumatoid arthritis. Ann Rheum Dis 1994;53:149.
24. Glass D, Snaith ML, Russell AS, Daly JR. Possible unnecessary prolongation of corticosteroid therapy with rheumatoid arthritis. Lancet 1971;2:334-7.
25. Heytman M, Ahern MJ, Smith MD, Roberts-Thomson PJ. The long term effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. J Rheumatol 1994;21:435-41.